Skip to content
Clinical Trials – home
HungaryBack to Hungary

Clinical trials in Sumeg – page 12

242 clinical trials in Sumeg, Hungary. Every trial is listed in the EU Clinical Trials Register and updated daily.

Sumeg at a glance
242
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

242 trials in Sumeg

Open in trial search

Study of Anifrolumab for Adults with Moderate-to-Severe Systemic Lupus Erythematosus

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Anifrolumab
  • Sponsor:Astrazeneca AB

Study of Olezarsen (ISIS 678354) in Patients with Severe Hypertriglyceridemia: Testing Effects on Triglyceride Levels

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:ISIS 678354 sodium salt
  • Sponsor:Ionis Pharmaceuticals Inc.

Study on the Effects of Budesonide, Glycopyrronium, and Formoterol Fumarate for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:Astrazeneca AB

Arteriosclerosis

Not recruiting

Study of inclisiran to prevent heart attacks and strokes in people with atherosclerotic cardiovascular disease

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Atorvastatin
  • Sponsor:Novartis Pharma AG

Migraine+3

Not recruiting

Study Comparing Atogepant and Topiramate for Preventive Treatment in Adults with Migraine

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Atogepant
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Ischaemic stroke+2

Not recruiting

Study on Asundexian for Preventing Ischemic Stroke in Adults After a Stroke or High-Risk Mini-Stroke

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Asundexian
  • Sponsor:Bayer AG

Arteriosclerosis

Not recruiting

Study on the Effect of Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease Not Adequately Managed by Current Lipid-Lowering Treatments

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Obicetrapib
  • Sponsor:NewAmsterdam Pharma B.V.

Study of GLPG3667 for Adults with Active Systemic Lupus Erythematosus

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:GLPG3667 fumarate
  • Sponsor:Lakefront Biotherapeutics

Psoriatic arthropathy

Not recruiting

Study on Deucravacitinib and Apremilast for Patients with Active Psoriatic Arthritis New to Biologic Treatments or Previously on TNFα Inhibitors

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Apremilast
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Psoriasis

Not recruiting

Study on the Effectiveness and Safety of JNJ-77242113 for Treating Moderate to Severe Plaque Psoriasis in Adults

Investigational
Countries:HungaryHungary
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Icotrokinra
  • Sponsor:Janssen - Cilag International

Psoriatic arthropathy

Not recruiting

Study on Deucravacitinib for Patients with Active Psoriatic Arthritis New to Biologic Treatments

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Rheumatoid arthritis

Not recruiting

Study Comparing Upadacitinib, Placebo, and Adalimumab for Patients with Moderate to Severe Rheumatoid Arthritis on Stable Methotrexate Treatment

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Other cities in Hungary

The busiest research cities in the country

All 73 cities in Hungary

Clinical research in Sumeg

What the registry says about research in the country

01 Movement Disorders Research

Clinical investigations focusing on tardive dyskinesia, a complex movement disorder characterized by involuntary muscle movements. The research aims to evaluate new therapeutic approaches for managing abnormal involuntary movements in patients with moderate to severe symptoms.

  • Movement Control Studies
  • Neurological Disorders
  • Therapeutic Intervention Assessment

These trials combine both open-label and controlled study designs to thoroughly assess treatment effectiveness for patients experiencing movement-related symptoms.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.